

Amendments to and Listing of the Claims:

Please amend claims 1-3, 7-12 and 14-24, without prejudice, cancel claims 13, 25 and 26, without prejudice, and add new claims 27-41, as set forth in the following listing of the claims, which replaces all prior listings of the claims.

1. (Currently Amended) Film-shaped A film-shaped medicament for buccal administration of galanthamine or a salt or derivative thereof, said medicament comprising at least one layer which contains containing a cholinergic active substance acting on the central nervous system or a combination of at least two such cholinergic active substances, said active substance(s) being selected from the group consisting of galanthamine, pharmaceutically acceptable salts of galanthamine, galanthamine derivatives and their pharmaceutically acceptable salts, and said film-shaped medicament being soluble in aqueous media and/or rapidly disintegrating in aqueous media, but not being mucoadhesive.
2. (Currently Amended) Film-shaped The film-shaped medicament according to claim 1, characterized in that wherein the said layer or at least one of the layers has a polymer matrix serving as an active substance reservoir, the polymer matrix-containing layer has a polymer content amounting to of 5 to 95%, preferably 15 to 75% wt, with particular preference 20 to 50% wt.
3. (Currently Amended) Film-shaped The film-shaped medicament according to claim 1, characterized in that wherein within 30 min, preferably within 15 min, with particular preference within 5 min after application of the medicament to an oral cavity, it the medicament releases such an amount of the active substance(s) contained therein to the oral cavity that an effective plasma level is achieved.

4-6. (Cancelled)

7. (Currently Amended) Film-shaped The film-shaped medicament according to claim 1, characterized in that it is being of a bilayer or multilayer structure, with at least one of the layers

containing the active substance.

8. (Currently Amended) Film-shaped The film-shaped medicament according to claim 1, characterized in that wherein at least one of the layers has a retarded active substance release.

9. (Currently Amended) Film-shaped The film-shaped medicament according to claim 1, characterized in that the wherein the active substance-containing layer(s) has an active substance content is of 0.1 to 30%-wt, preferably 1 to 20%-wt, each relative to the active substance-containing layer(s).

10. (Currently Amended) Film-shaped The film-shaped medicament according to claim 1, characterized in that wherein the medicament contains galanthamine, or a salt or derivative of galanthamine, in combination with at least one further pharmaceutically active substance, preferably selected from the group of the acetylcholinesterase inhibitors.

11. (Currently Amended) Film-shaped The film-shaped medicament according to claim 1, characterized in that its wherein the thickness of the layer thickness is 0.01 to 5 mm, preferably 0.03 to 2 mm, with particular preference 0.05 to 1 mm.

12. (Currently Amended) Film-shaped The film-shaped medicament according to claim 1, characterized in that it contains containing one or more auxiliaries selected from the group consisting of fillers, colourants, emulsifiers, plasticizers, disintegration promoters, disintegrants (wick agents), wetting agents, sweetening and flavouring agents, preservatives, pH regulators, permeation-enhancing substances and antioxidants.

13. (Cancelled)

14. (Currently Amended) Use The method according to claim 27,13, characterized in that the said wherein the film-shaped medicament is a medicament comprising comprises at least one layer which contains said containing the cholinergic active agent or a the combination of at least two such-cholinergic active agents and said the film-shaped medicament being is soluble in

aqueous media and/or rapidly disintegrating disintegrates in aqueous media, but is not being mucoadhesive.

15. (Currently Amended) Use The method according to claim 27,13, characterized in that the wherein said disease is Alzheimer's disease or that the said-symptom is impaired memory occurring in the course of Alzheimer's disease.
16. (Currently Amended) Use The method according to claim 27-13, characterized in that the said treatment is the being a therapy of alcohol abuse, especially a treatment for reducing the craving for alcohol, or the therapy of nicotine abuse, especially a treatment for reducing the craving for nicotine.
17. (Currently Amended) Use The method according to claim 27 13, characterized in that the said treatment is being an antidote treatment following neuroleptic anaesthesia.
18. (Currently Amended) Use The method according to claim 2713, characterized in that the said treatment is being a therapy of abuse of chemical substances or of the dependence on such chemical substances, especially a therapy of intoxication with psychotropic substances.
19. (Currently Amended) Use The method according to claim 27,13, characterized in that the said symptoms or diseases are symptoms wherein the disease or symptom is a symptom of jet lag or other disorders another disorder of the physiological rhythm of body functions.
20. (Currently Amended) Use The method according to claim 27,13, characterized in that the said symptoms or diseases are wherein the disease or symptom is chronic fatigue syndrome or disturbed sleep.
21. (Currently Amended) Use The method according to claim 27, 13, characterized in that the wherein said disease is schizophrenia or a mania.
22. (Currently Amended) Use The method according to claim 27,13, characterized in that the

said symptoms or diseases are neurological illnesses and symptoms, especially paralytic symptoms wherein the disease or symptom is a neurological illness and symptom.

23. (Currently Amended) Use The method according to claim 27,13, characterized in that the medicament is being used for the treatment of disorders of the central nervous system occurring as a consequence of the action of psychotropic substances caused by occasional or chronic use or abuse of addictive substances, narcotics or medicaments, or as a side effect of the use of medicaments as intended, especially repeated or prolonged use of medicaments, or as a consequence of acute poisoning, or as a consequence of the chronic action of poisons, in humans or other vertebrates.
24. (Currently Amended) Use The method according to claim 23, characterized in that the said symptoms are symptoms wherein the disease or symptom is selected from the group consisting of cognitive disorders, especially impaired memory, as well as impairment of memory performance, impaired perception, and impaired coordination of movements.
25. (Cancelled)
26. (Cancelled)
27. (New) A method of treating a disease or symptom accompanied or caused by a lack of acetylcholine-induced conduction and/or a disturbed regulation of a neuronal nicotinic receptor in a subject, the method comprising buccally administering to the subject a film-shaped medicament, the medicament comprising a therapeutically effective dose of at least one cholinergic active agent or a combination of at least two cholinergic active agents, the cholinergic active agent(s) being selected from the group consisting of galanthamine, pharmaceutically acceptable salts of galanthamine, galanthamine derivatives and their pharmaceutically acceptable salts.
28. (New) The film-shaped medicament according to claim 2, wherein the polymer content is 15 to 75%-wt.

29. (New) The film-shaped medicament according to claim 2, wherein the polymer content is 20 to 50%-wt.

30. (New) The film-shaped medicament according to claim 3, wherein the effective plasma level is achieved within 15 min after the application of the medicament to the oral cavity.

31. (New) The film-shaped medicament according to claim 3, wherein the effective plasma level is achieved within 5 min after the application of the medicament to the oral cavity.

32. (New) The film-shaped medicament according to claim 9, wherein the active substance content is 1 to 20%-wt.

33. (New) The film-shaped medicament according to claim 10, wherein the further pharmaceutically active substance is selected from the group consisting of acetylcholinesterase inhibitors.

34. (New) The film-shaped medicament according to claim 11, wherein the thickness of the layer is 0.03 to 2 mm.

35. (New) The film-shaped medicament according to claim 11, wherein the thickness of the layer is 0.05 to 1 mm.

36. (New) The method according to claim 16 being a treatment for reducing the craving for alcohol or a therapy of nicotine abuse.

37. (New) The method according to claim 36 being a treatment for reducing the craving for nicotine.

38. (New) The method according to claim 18 being a therapy for intoxication with psychotropic substances.

39. (New) The method according to claim 22, wherein the disease or symptom is a paralytic symptom.

40. (New) The method according to claim 23, being used for the treatment of disorders of the central nervous system occurring as a side effect of repeated or prolonged use of medicaments in humans or other vertebrates.

41. (New) The method according to claim 24, wherein the cognitive disorder is impaired memory.